Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

161.16 +0.56 (+0.35%)
Streaming Delayed Price Updated: 1:34 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,714,406
Open 160.24
Bid (Size) 161.16 (1)
Ask (Size) 161.17 (1)
Prev. Close 160.60
Today's Range 160.02 - 161.54
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Why Masimo Stock Crushed the Market Today
The company seems to be effecting a smooth transition in its leadership. 
Via The Motley Fool

Performance

YTD
+0.74%
+0.74%
1 Month
-2.10%
-2.10%
3 Month
+9.77%
+9.77%
6 Month
+2.03%
+2.03%
1 Year
+1.35%
+1.35%

More News

Read More
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
Via Chartmill
The Latest Analyst Ratings For Johnson & Johnson
Via Benzinga
Unpacking the Latest Options Trading Trends in Johnson & Johnson
Via Benzinga
Is Johnson & Johnson Stock a Buy?
Via The Motley Fool
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Via Benzinga
Exposures Product Safety
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
Via Benzinga
Exposures Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
Via The Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Via Benzinga
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
Via The Motley Fool
How To Earn $500 A Month From Johnson & Johnson Stock
Via Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
Via Benzinga
Exposures Product Safety
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Via Benzinga
3 Safe Stocks with Safe Dividends for Your Portfolio
Via MarketBeat
Topics Economy
Exposures Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.